🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

505 results for “Oral” Clear

  1. Ibutamoren Mesylate, Ibutamoren Mesylate, Matched placebo capsules administered orally once per day, Ibutamoren Mesylate

    Lacuna Pharma Pty Ltd

    Growth Hormone Deficiency (GHD)

    phase 3 small molecule active

    1 trial

  2. In-person Cognitive Behavioral Therapy of Insomnia

    United Therapeutics Europe Ltd

    Insomnia

    phase 3 other completed

    1 trial

  3. Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)

    Disc Medicine

    Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)

    phase 3 small molecule active

    1 trial

  4. KP415 oral capsule

    ZEVRA THERAPEUTICS, INC.

    ADHD

    phase 3 small molecule completed

    2 trials

  5. LI

    Teva Pharma GmbH

    Squamous Cell Carcinoma of the Oral Cavity

    phase 3 mab completed

    1 trial

  6. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  7. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEEs)

    phase 3 small molecule active

    1 trial

  8. Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Oral Contraceptive

    phase 3 small molecule active

    1 trial

  9. Levosimendan, The levosimendan placebo drug product is an immediate-release dosage form for oral administration.

    TENAX THERAPEUTICS, INC.

    Pulmonary Hypertension (PH) with Heart Failure with preserved left ventricular ejection fraction (PH-HFpEF)

    phase 3 small molecule active

    1 trial

  10. Lokelma 5 g powder for oral suspension, Lokelma 10 g powder for oral suspension

    The George Institute

    Hyperkalemia in patients with chronic kidney disease

    phase 3 small molecule active

    1 trial

  11. Losmapimod oral tablet

    Fulcrum Therapeutics

    COVID-19

    phase 3 small molecule terminated

    1 trial

  12. MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial

  13. MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT

    Lacuna Pharma Pty Ltd

    Anemia in subjects with sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  14. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  15. Mexiletine granules for prolonged-release oral suspension 333 mg, Mexiletine granules for prolonged-release oral suspension 167 mg, Mexiletine granules for prolonged-release oral suspension 500 mg

    Lupin Europe GmbH

    Myotonic Dystrophy type 1 and type 2 (DM1/DM2)

    phase 3 small molecule active

    1 trial

  16. NBI-74788, Crinecerfont placebo for oral capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  17. NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  18. NPC-11 for intravenous or oral administration.

    Belpharma s.a.

    Apnea of Prematurity

    phase 3 small molecule completed

    1 trial

  19. Namuscla 167 mg hard capsules, Mexiletine granules for prolonged-release oral suspension 167 mg, Mexiletine granules for prolonged-release oral suspension 500 mg, Mexiletine granules for prolonged-release oral suspension 333 mg

    Lupin Europe GmbH

    Non-Dystrophic Myotonias (NDM)

    phase 3 small molecule active

    1 trial

  20. Nano-crystalline Megestrol Acetate Oral Suspension

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  21. ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON

    Karyopharm Therapeutics Inc

    Treatment naïve patients with MF

    phase 3 small molecule active

    1 trial

  22. Oral Budesonide Suspension (OBS)

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule completed

    2 trials

  23. Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.

    United Therapeutics Europe Ltd

    Non-Severe Pneumonia

    phase 3 small molecule completed

    1 trial

  24. Oral Treprostinil

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources